Piper Sandler downgraded shares of Kronos Bio (NASDAQ:KRON – Free Report) from an overweight rating to a neutral rating in a research report released on Thursday, Marketbeat Ratings reports. The firm currently has $1.00 target price on the stock, down from their prior target price of $6.00.
KRON has been the topic of several other research reports. TD Cowen cut Kronos Bio from a “buy” rating to a “hold” rating in a research note on Thursday. HC Wainwright reissued a “buy” rating and set a $2.25 price target on shares of Kronos Bio in a research report on Monday, August 19th.
View Our Latest Stock Report on KRON
Kronos Bio Stock Performance
Hedge Funds Weigh In On Kronos Bio
Large investors have recently bought and sold shares of the business. Virtu Financial LLC bought a new position in shares of Kronos Bio during the first quarter valued at approximately $71,000. Forefront Analytics LLC boosted its position in Kronos Bio by 75.0% during the 2nd quarter. Forefront Analytics LLC now owns 134,998 shares of the company’s stock valued at $167,000 after purchasing an additional 57,867 shares during the period. Acadian Asset Management LLC grew its stake in Kronos Bio by 17.2% during the 1st quarter. Acadian Asset Management LLC now owns 774,559 shares of the company’s stock worth $1,005,000 after buying an additional 113,618 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in Kronos Bio by 14.6% in the first quarter. Vanguard Group Inc. now owns 1,948,595 shares of the company’s stock worth $2,533,000 after buying an additional 247,918 shares during the period. Institutional investors own 64.09% of the company’s stock.
About Kronos Bio
Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.
Further Reading
- Five stocks we like better than Kronos Bio
- Upcoming IPO Stock Lockup Period, Explained
- Warren Buffett, Cathie Wood Own Nu Holdings, Should You?
- What Does Downgrade Mean in Investing?
- MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?
- The How and Why of Investing in Gold Stocks
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Receive News & Ratings for Kronos Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kronos Bio and related companies with MarketBeat.com's FREE daily email newsletter.